Ming Jen Lu

6362011, Mar 26, 2002

Feb 2, 1999

09/243215

Richard J. Massey - Rockville MD
Mark T. Martin - Bethesda MD
Liwen Dong - Rockville MD
Ming Lu - Lanham MD
Alan Fischer - Cambridge MA
Fabian Jameison - Gaithersburg MD
Pam Liang - Rockville MD
Robert Hoch - Hensonville NY
Jonathan K. Leland - Silver Spring MD

Meso Scale Technologies, LLC - Gaithersburg MD

G01N 33551

436526, 435 6, 435 74, 435 75, 435 792, 435 793, 435 794, 435 24, 435 26, 435176, 435182, 436524, 436535, 436806, 5303911, 5303913, 5303915

Graphitic nanotubes, which include tubular fullerenes (commonly called âbuckytubesâ) and fibrils, which are functionalized by chemical substitution, are used as solid supports in electrogenerated chemiluminescence assays. The graphitic nanotubes are chemically modified with functional group biomolecules prior to use in an assay. Association of electrochemiluminescent ruthenium complexes with the functional group biomolecule-modified nanotubes permits detection of molecules including nucleic acids, antigens, enzymes, and enzyme substrates by multiple formats.

7052861, May 30, 2006

Dec 5, 2001

10/007526

Richard J. Massey - Rockville MD, US
Mark T. Martin - N. Bethesda MD, US
Liwen Dong - Rockville MD, US
Ming Lu - Lanham MD, US
Alan Fischer - Cambridge MA, US
Fabian Jameison - Gaithersburg MD, US
Pam Liang - Baltimore MD, US
Robert Hoch - Hensonville NY, US
Jonathan K. Leland - Silver Spring MD, US

Meso Scale Technologies, LLC. - Gaithersburg MD

G01N 33/573
G01N 33/533
G01N 33/553
G01N 21/76
C12Q 1/32

435 74, 435 26, 435968, 436172, 436524, 436526, 436546, 436805

Graphitic nanotubes, which include tubular fullerenes (commonly called “buckytubes”) and fibrils, which are functionalized by chemical substitution, are used as solid supports in electrogenerated chemiluminescence assays. The graphitic nanotubes are chemically modified with functional group biomolecules prior to use in an assay. Association of electrochemiluminescent ruthenium complexes with the functional group biomolecule-modified nanotubes permits detection of molecules including nucleic acids, antigens, enzymes, and enzyme substrates by multiple formats.

20020174395, Nov 21, 2002

May 21, 2001

09/861740

Wen-Yi Kuo - Morganville NJ, US
Gang Li - Bridgewater NJ, US
Ming Lu - Hillsborough NJ, US
Martin Meyers - Montclair NJ, US

H04L001/18
G08C025/02

714/748000

In a system of communication, a sending node sends a message to a receiving node, which NAKs unsuccessful transmissions. The sending node screens the NAKs to determine if they were sent before the receiver could receive previous transmissions of the same data NAKed. One screening technique is based on an estimated round trip time of a message. Another alternate technique looks a flag in the NAK that synchronizes the sender and the receiver.

20060160246, Jul 20, 2006

Mar 20, 2006

11/385277

Richard Massey - Rockville MD, US
Mark Martin - N. Bethesda MD, US
Liwen Dong - Rockville MD, US
Ming Lu - Lanham MD, US
Alan Fischer - Cambridge MA, US
Fabian Jameison - Gaithersburg MD, US
Pam Liang - Baltimore MD, US
Robert Hoch - Hensonville NY, US
Jonathan Leland - Silver Spring MD, US

G01N 33/543
C12M 1/34

436518000, 435287200, 977746000

Graphitic nanotubes, which include tubular fullerenes (commonly called “buckytubes”) and fibrils, which are functionalized by chemical substitution, are used as solid supports in electrogenerated chemiluminescence assays. The graphitic nanotubes are chemically modified with functional group biomolecules prior to use in an assay. Association of electrochemiluminescent ruthenium complexes with the functional group biomolecule-modified nanotubes permits detection of molecules including nucleic acids, antigens, enzymes, and enzyme substrates by multiple formats.

20080261243, Oct 23, 2008

Oct 6, 2005

11/575811

Robert M. Lorence - Bethesda MD, US
Ming Lu - Potomac MD, US

WELLSTAT BIOLOGICS CORPORATION - Gaitherbsurg MD

G01N 33/574

435 723

The expression of Her-2/neu protein on circulating cancer cells in a blood sample is detected by isolating the cancer cells from the blood sample and then performing on the isolated cancer cells a sensitive Her-2/neu immunoassay. A positive result indicates the expression of Her-2/neu on cancer cells in the blood sample. This method can be used to identify cancer patients who are likely to benefit from treatment with an anticancer agent that targets Her-2/neu, such as trastuzumab (HERCEPTIN).

20090291920, Nov 26, 2009

Apr 18, 2007

12/296458

Ming Lu - Potomac MD, US
Robert M. Lorence - Bethesda MD, US

WELLSTAT BIOLOGICS CORPORATION - Gaithersburg MD

A61K 31/566
C12Q 1/02
A61K 31/565
A61K 31/4353
A61K 31/4196

514 77, 435 29, 514182, 514300, 514383

The expression of a steroid receptor from circulating carcinoma cells in a blood sample is detected by isolating the carcinoma cells from the blood sample, making an extract from the isolated carcinoma cells and then performing on the extract a sensitive immunoassay capable of detecting the carcinoma cell-associated steroid receptor. A positive result indicates the presence of the steroid receptor in the carcinoma cells. This method can be used to identify cancer patients who are likely to benefit from treatment with an endocrine therapeutic agent.

20100120072, May 13, 2010

Apr 15, 2008

12/593160

Robert M. Lorence - Bethesda MD, US
Ming Lu - Potomac MD, US

WELLSTAT BIOLOGICS CORPORATION - Gaithersburg MD

G01N 33/574

435 723

The expression of Her-2/neu protein on circulating cancer cells in a sample of blood or peripheral blood mononuclear cells (PBMCs) is detected by performing a sensitive Her-2/neu immunoassay. There is no need to isolate the cancer cells before performing the immunoassay. A positive result indicates the expression of Her-2/neu on cancer cells in the blood sample. This method can be used to identify cancer patients who are likely to benefit from treatment with an anticancer agent that targets Her-2/neu, such as trastuzumab (HERCEPTIN), lapatinib, CP-724,714, NKI-272, and BMS-599626

20110070598, Mar 24, 2011

Feb 18, 2010

12/708159

Robert M. Lorence - Bethesda MD, US
Ming Lu - Potomac MD, US

WELLSTAT BIOLOGICS CORPORATION - Gaithersburg MD

G01N 33/574
G01N 33/577

435 723

The expression of Her-2/neu protein on circulating cancer cells in a blood sample is detected by isolating the cancer cells from the blood sample and then performing on the isolated cancer cells a sensitive Her-2/neu immunoassay. A positive result indicates the expression of Her-2/neu on cancer cells in the blood sample. This method can be used to identify cancer patients who are likely to benefit from treatment with an anticancer agent that targets Her-2/neu, such as trastuzumab (HERCEPTIN).